A string of high-profile FDA rejections recently prompted biopharma followers to wonder whether the US drugs regulator was finally showing its teeth after a period of perceived leniency. This idea is not supported by the raw numbers, however.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,